Bipolar disorder psychedelic and ketamine research trials
If you are thinking about suicide or are in crisis, please get help now. Call your local emergency number, or a crisis line: in the US call or text 988, in the UK and Ireland call Samaritans on 116 123, in Israel call ERAN on 1201. For other countries, search for findahelpline.com.
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
45 registered studies are counted for bipolar disorder. By compound: 5 psilocybin, 1 LSD, 1 5-MeO-DMT and 39 ketamine. By registry status: 6 recruiting, 1 enrolling by invitation, 5 active, not recruiting, 19 completed, 6 terminated, 2 suspended, 1 withdrawn and 5 status not reported. By phase: 2 early phase 1, 4 phase 1, 14 phase 2, 6 phase 3, 5 phase 4, 6 not applicable and 8 not reported. Reported start years run from 2009 (earliest) to 2026 (latest).
This page includes bipolar I and II disorder and bipolar depression when the title names bipolar disorder. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 45 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 5 |
| LSD | 1 |
| 5-MeO-DMT | 1 |
| Ketamine | 39 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 6 | 13% |
| Enrolling by invitation | 1 | 2% |
| Active, not recruiting | 5 | 11% |
| Completed | 19 | 42% |
| Terminated | 6 | 13% |
| Suspended | 2 | 4% |
| Withdrawn | 1 | 2% |
| Status not reported | 5 | 11% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 2 | 4% |
| Phase 1 | 4 | 9% |
| Phase 2 | 14 | 31% |
| Phase 3 | 6 | 13% |
| Phase 4 | 5 | 11% |
| Not applicable | 6 | 13% |
| Not reported | 8 | 18% |
Countries
Country is taken from the study's linked research site. 1 of 45 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 22 | 49% |
| Canada | 12 | 27% |
| Israel | 2 | 4% |
| Poland | 2 | 4% |
| Brazil | 1 | 2% |
| China | 1 | 2% |
| Germany | 1 | 2% |
| United Kingdom | 1 | 2% |
| Ireland | 1 | 2% |
| Iran | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 10 |
| 2020 to 2023 | 15 |
| 2015 to 2019 | 13 |
| 2010 to 2014 | 6 |
| Before 2010 | 1 |
Study design
- 37 interventional and 8 observational studies.
- Median planned or actual enrolment is 31 participants (range 1 to 1,254, across 44 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | NCT07569198 | Recruiting | Phase 2 | 2026-06-01 | Ketamine |
| Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder | NCT06943573 | Recruiting | Phase 3 | 2025-10-01 | Psilocybin |
| Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality | NCT06706232 | Recruiting | Phase 2 | 2025-07-07 | Psilocybin |
| Treatment Response In ECT Patients | NCT07463911 | Active, not recruiting | Not reported | 2025-05-20 | Ketamine |
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure | NCT05603104 | Recruiting | Phase 3 | 2025-04-27 | Ketamine |
| Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions | NCT06823024 | Enrolling by invitation | Not reported | 2025-02-18 | Ketamine |
| FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression | NCT06620042 | Completed | Phase 2 | 2024-11-12 | Ketamine |
| Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression | NCT06506019 | Active, not recruiting | Phase 1 | 2024-10-09 | Psilocybin, LSD |
| Behavioural Activation Therapy and Esketamine for Resistant Depression | NCT06431386 | Terminated | Not applicable | 2024-06-11 | Ketamine |
| Predictors of Intravenous Ketamine Response in TRD | NCT05625555 | Active, not recruiting | Phase 3 | 2024-01-19 | Ketamine |
| Phase 2 Clinical Trial of GH001 in Bipolar II Disorder | NCT05839509 | Terminated | Phase 2 | 2023-04-06 | 5-MeO-DMT |
| The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects | NCT05786066 | Recruiting | Phase 2 | 2023-04-03 | Ketamine |
| Maintenance Ketamine Infusions for Treatment-Resistant Bipolar Depression | NCT05339074 | Completed | Phase 2 | 2022-08-11 | Ketamine |
| Ketamine for Treatment-Resistant Bipolar Disorder | NCT05004896 | Completed | Phase 2 | 2022-07-04 | Ketamine |
| Neural Correlates of Ketamine's Anti-suicidal Effects in Bipolar Depression | NCT05177146 | Completed | Not applicable | 2022-05-04 | Ketamine |
| Psilocybin Therapy for Depression in Bipolar II Disorder | NCT05065294 | Active, not recruiting | Phase 2 | 2022-01-28 | Psilocybin |
| Synaptic Imaging and Network Activity in Treatment Resistant Depression | NCT05870501 | Completed | Not applicable | 2021-10-20 | Ketamine |
| Ketamine As an Adjunctive Therapy for Major Depression (2) | NCT04939649 | Completed | Phase 3 | 2021-09-13 | Ketamine |
| Naturalistic Study of Ketamine in the Treatment of Depression | NCT05249309 | Status not reported | Not reported | 2021-05-01 | Ketamine |
| The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. | NCT04433845 | Status not reported | Phase 2 | 2021-03-01 | Psilocybin |
| IM Ketamine vs Midazolam for Suicidal ER Patients | NCT04640636 | Suspended | Phase 4 | 2021-02-09 | Ketamine |
| Music as an Intervention to Improve Hemodynamic Tolerability of Ketamine in Depression | NCT04701866 | Completed | Not applicable | 2021-01-11 | Ketamine |
| University of Iowa Interventional Psychiatry Service Patient Registry | NCT04480918 | Recruiting | Not reported | 2020-11-02 | Ketamine |
| The Effect of S-ketamine for Patients Undergoing Electroconvulsive Therapy (ECT) | NCT04399070 | Status not reported | Not applicable | 2020-08-01 | Ketamine |
| 2-Year Study of Vagus Nerve Stimulation for Higher-Grade Treatment-Resistant Depression: Clinical Outcomes and Policy Recommendation | NCT07097025 | Completed | Not reported | 2020-01-01 | Ketamine |
| A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders | NCT04226963 | Completed | Not reported | 2019-12-04 | Ketamine |
| Chart Review of Patients Undergoing Ketamine Infusions | NCT04209296 | Completed | Not reported | 2019-12-03 | Ketamine |
| NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression | NCT03396601 | Status not reported | Phase 3 | 2019-06-25 | Ketamine |
| Open Study of the Neurobiological Effects of Intranasal Ketamine in Children and Adults With Bipolar Disorder | NCT05209217 | Status not reported | Not reported | 2019-06-04 | Ketamine |
| Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Bipolar Depression | NCT03965871 | Completed | Phase 2 | 2019-03-28 | Ketamine |
| Ketamine Associated ACC GABA and Glutamate Change and Depression Remission: | NCT03573349 | Active, not recruiting | Early Phase 1 | 2019-01-03 | Ketamine |
| Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial | NCT03367533 | Completed | Phase 1 | 2018-11-29 | Ketamine |
| Ketamine Versus Electroconvulsive Therapy in Depression | NCT03674671 | Suspended | Phase 3 | 2018-10-29 | Ketamine |
| Sequential Therapy for the Treatment of Severe Bipolar Depression. | NCT02974010 | Completed | Phase 2 | 2018-01-15 | Ketamine |
| Ketamine as an Adjunctive Therapy for Major Depression | NCT03256162 | Completed | Phase 1 | 2017-09-07 | Ketamine |
| The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression. | NCT03156504 | Completed | Phase 4 | 2017-06-01 | Ketamine |
| The UTHealth Ketamine Project | NCT02882711 | Terminated | Phase 2 | 2016-11-07 | Ketamine |
| Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | NCT02593643 | Completed | Early Phase 1 | 2016-01-01 | Ketamine |
| Ketamine for Suicidality in Bipolar Depression | NCT01944293 | Completed | Phase 1 | 2013-09-01 | Ketamine |
| NMDA Antagonists in Bipolar Depression | NCT01833897 | Completed | Phase 4 | 2013-03-01 | Ketamine |
| Trial of Ketamine and Lithium Therapy in Bipolar Depression | NCT01768767 | Withdrawn | Phase 2 | 2013-01-01 | Ketamine |
| Intranasal Ketamine In the Treatment of Pediatric Bipolar Disorder | NCT01504659 | Terminated | Phase 2 | 2012-07-01 | Ketamine |
| Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression | NCT01881763 | Completed | Phase 4 | 2010-06-01 | Ketamine |
| Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression | NCT01309581 | Terminated | Not applicable | 2010-04-01 | Ketamine |
| Treatment Study of Bipolar Depression | NCT00947791 | Terminated | Phase 4 | 2009-07-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | LSD | 5-MeO-DMT | Ketamine
Other condition hubs
Depression | Treatment-resistant depression | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk